[Pore-forming leukotoxins from Staphylococcus aureus: variability of the target cells and 2 pharmacological processes].
The staphylococcal bi-component leukotoxins constitute a family included in the super-family of the beta-sheet-structured pore-forming toxins. They may be produced by Staphylococcus aureus and by Staphylococcus intermedius and their target cells vary according to the molecules. The mode of action proceeds by the sequential binding of the class S proteins, then by that of the class F proteins at the surface of the membranes. Then, the activation of cellular calcium-channels precedes the pore formation which seems to be sensitive to several monovalent cations. The cell response is inflammatory and includes the neosynthesis as well as the secretion of leukotriene B4, interleukin -8, histamine. The injection of leukotoxins to rabbits generates cell chemotaxis , vasodilatation, and tissue necrosis. The association of the production of leukotoxins with clinical syndromes concerns several aspects of the pathology of S. aureus, and confers to these leukotoxins an important role of virulence factors.
Laboratoire de Toxinologie et d'Antibiologie Bactériennes (LTAB-UPRES-EA 1318), Université Louis Pasteur, Hôpitaux Universitaires de Strasbourg, France.
G
G
Prévost
D A
DA
Colin
L
L
Staali
L
L
Baba Moussa
A
A
Gravet
S
S
Werner
A
A
Sanni
O
O
Meunier
H
H
Monteil
D000818:Animals; D001426:Bacterial Proteins / Q000378:metabolism / Q000494:pharmacology*; D001427:Bacterial Toxins / Q000378:metabolism / Q000494:pharmacology*; D015220:Calcium Channels / Q000378:metabolism; D002413:Cations, Divalent / Q000378:metabolism; D002417:Cattle; D002463:Cell Membrane Permeability / Q000187:drug effects*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D003428:Cross Infection / Q000473:pathology / Q000503:physiopathology; D004912:Erythrocytes / Q000187:drug effects*; D005098:Exotoxins; D005260:Female; D006460:Hemolysin Proteins; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism; D017136:Ion Transport; D007956:Leukocidins / Q000378:metabolism / Q000494:pharmacology*; D007975:Leukotriene B4 / Q000378:metabolism; D008297:Male; D008414:Mastitis, Bovine / Q000503:physiopathology; D008954:Models, Biological; D009336:Necrosis; D009504:Neutrophils / Q000187:drug effects*; D011817:Rabbits; D013203:Staphylococcal Infections / Q000473:pathology / Q000503:physiopathology / Q000662:veterinary; D013211:Staphylococcus aureus / Q000378:metabolism*; D013601:T-Lymphocytes / Q000187:drug effects*; D014664:Vasodilation / Q000187:drug effects; D014774:Virulence; D014822:Vitreous Body
D001426:Bacterial Proteins; D001427:Bacterial Toxins; D015220:Calcium Channels; D002413:Cations, Divalent; D005098:Exotoxins; D006460:Hemolysin Proteins; D016209:Interleukin-8; D007956:Leukocidins; C091659:LukM protein, Staphylococcus aureus; C078284:Panton-Valentine leukocidin; C037956:gamma-hemolysin, Staphylococcus aureus; C108483:leukocidin S-component protein, Staphylococcus; C074300:LukF protein, Staphylococcus aureus; D007975:Leukotriene B4
Les leucotoxines formant des pores de Staphylococcus aureus: variabilité des cellules-cible et deux processus pharmacologiques.